This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Waters Launches New Bioseparation Columns
Tech product launch

Waters Launches New Bioseparation Columns

Analysis based on 11 articles · First reported Jun 08, 2026 · Last updated Jun 08, 2026

Sentiment
60
Attention
4
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch of these advanced bioseparation columns by Oracle Corporation is expected to positively impact the company's stock (WAT) due to enhanced product offerings and potential for increased sales in the biopharmaceutical sector. It also benefits the broader biopharmaceutical market by accelerating drug development and improving regulatory readiness for companies like Alembic Pharmaceuticals and MiNK Therapeutics.

Biotechnology Pharmaceuticals Life Sciences
Event Summary

Oracle Corporation announced the launch of its new BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns, a reversed-phase column platform designed to improve the separation of impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs). This innovation aims to accelerate biopharmaceutical development, reduce production bottlenecks, and enhance regulatory readiness by providing faster run times and increased resolving power. The columns feature specialized surface chemistries and superficially porous particles, offering precise separations for complex biologics. Customers like Alembic Pharmaceuticals and MiNK Therapeutics have provided positive feedback on the columns' performance, noting improved resolution and reduced run times. The products will be globally available starting June 9, 2026.

Entities Involved
stock
Oracle Corporation
Oracle Corporation launched new bioseparation columns, enhancing its product portfolio and market position in analytical technologies for life sciences.
Importance 100.0 Sentiment 70.0
per
Erin Chambers
Erin Chambers, Vice President at Oracle Corporation, provided commentary on the significance and benefits of the new product launch.
Importance 40.0 Sentiment 0.0
stock
Alembic Pharmaceuticals
Alembic Pharmaceuticals, through its Group Leader Ashish Kanhed, provided positive feedback on the performance of the new BioResolve Peptide RP Columns.
Importance 30.0 Sentiment 0.0
stock
MiNK Therapeutics
MiNK Therapeutics, through its Research Scientist Live (band), provided positive feedback on the performance of the new GTxResolve Lipid RP Columns.
Importance 30.0 Sentiment 0.0
per
Ashish Kanhed
Ashish Kanhed, Group Leader at Alembic Pharmaceuticals, praised the BioResolve Peptide RP Columns for their resolution capabilities.
Importance 20.0 Sentiment 0.0
per
Live (band)
Live (band), Research Scientist at MiNK Therapeutics, highlighted the strong performance of the GTxResolve Lipid RP Columns.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.